Longitudinal telomere length and body composition in healthy term-born infants during the first two years of life

Kirsten S. de Fluiter
Veryan Codd
Matthew Denniff
Gerthe F. Kerkhof
Inge A.L.P. van Beijsterveldt
Laura M. Breij
Nilesh J. Samani
Marieke Abrahamse-Berkeveld
Anita C.S. Hokken-Koelega

PLOS ONE 2021 2021;16(2):e0246400
ABSTRACT

Objective Leukocyte telomere length (LTL) is one of the markers of biological aging as shortening occurs over time. Shorter LTL has been associated with adiposity and a higher risk of cardiovascular diseases. The objective was to assess LTL and LTL shortening during the first 2 years of life in healthy, term-born infants and to associate LTL shortening with potential stressors and body composition.

Study design In 145 healthy, term-born infants (85 boys), we measured LTL in blood, expressed as telomere to single-gene copy ratio (T/S ratio), at 3 months and 2 years by quantitative PCR technique. Fat mass (FM) was assessed longitudinally by PEAPOD, DXA, and abdominal FM by ultrasound.

Results LTL decreased by 8.5% from 3 months to 2 years (T/S ratio 4.10 vs 3.75, p<0.001). LTL shortening from 3 months to 2 years associated with FM% (R=0.254), FM index (R=0.243) and visceral FM (R=0.287) at 2 years. LTL shortening tended to associate with gain in FM% from 3 to 6 months (R=0.155, p=0.11), in the critical window for adiposity programming. There was a trend to a shorter LTL in boys at 2 years (p=0.056). LTL shortening from 3 months to 2 years was not different between sexes.

Conclusion We present longitudinal LTL values and show that LTL shortens considerably (8.5%) during the first 2 years of life. LTL shortening during first 2 years of life was associated with FM%, FMI and visceral FM at age 2 years, suggesting that adverse adiposity programming in early life could contribute to more LTL shortening.
INTRODUCTION

Telomeres are noncoding repetitive DNA sequences at the end of chromosomes, protecting genomic DNA by maintaining stability (1). Due to the inability of DNA polymerase to fully replicate the ends of chromosomes, telomeres shorten with each cell division, thus with increasing age. When telomeres are reduced to a critical length, cells enter a state of arrest (cell senescence) (2). Telomere length can thus be used as a proxy of biological aging and mortality (3), although it is not the only biomarker of aging.

The shortening of leukocyte telomere length (LTL) can be accelerated by multiple factors, such as inflammation, (oxidative) stress, obesity, toxins and radiation (4). Shorter telomeres are associated with an increased risk for cardiovascular diseases (CVD), but it is uncertain if telomere length can be seen as a prognostic marker for CVD (3).

A rapid rise in weight during early life has also been associated with an increased risk for adiposity and CVD in adulthood (5-9). We have shown that a rapid rise in FM% SDS during the first 6 months of life, the critical window for adiposity programming, results in higher FM% trajectories during infancy (10). No associations were found between body size at birth and LTL in adulthood (11), but it is yet unknown whether LTL and its changes over time are associated with longitudinally measured body composition during infancy and the gain in FM% during the critical window for adiposity programming.

Until now, one other study has investigated leukocyte telomere length (LTL) longitudinally in healthy, term-born infants during the first two years of life (12), which is an important period for infant development (13). This study, however, did not investigate longitudinal LTL in association with body composition. Some studies in infants and children measured telomere length in cord blood directly after birth (14-16) or in childhood (17). Obtaining longitudinal values for LTL in healthy, term-born infants in early life in association with longitudinal body composition measures is important for clinical and research use. Various conditions and syndromes are linked to altered telomere length and adverse body composition, for example in infants born prematurely (18), small-for-gestational age (15) and infants with various syndromes (19).

The primary objective of this study was to investigate longitudinal LTL from age 3 months to 2 years. Our secondary objective was to investigate associations of LTL with potential influencing factors like gestational age, birth size and parity and with longitudinal body composition and abdominal fat mass during the first 2 years of life. We hypothesized that infants with more fat mass and particularly more visceral fat mass have more shortening in LTL during the first 2 years of life.
METHODS

Participants
The study population consisted of healthy, term-born infants, participating in the Sophia Pluto Study, a birth cohort study in Rotterdam area (The Netherlands). Between January 2013 and October 2019, infants were recruited from obstetric departments of regional hospitals and primary health care centers and detailed data on body composition and growth during early life were obtained. The Sophia Pluto Study obtained approval by the Medical Ethics Committee of Erasmus Medical Center and parental written informed consent was obtained for every participant.

All participants fulfilled the following inclusion criteria: term born (≥ 37 weeks of gestation), age < 28 days, uncomplicated neonatal period without signs of severe asphyxia (defined as an Apgar score < 3 after 5 minutes) and no sepsis or long-term complication of respiratory ventilation. Infants were excluded if they had known congenital or postnatal diseases, confirmed intrauterine infection, maternal use of corticosteroids during pregnancy or a significant maternal medical condition that could interfere with the study results.

Data Collection and Measures
Outpatient clinic visits were scheduled at age 1, 3, 6, 9, 12, 18 and 24 months (Table 1). Data on pregnancy and birth outcomes were obtained and measurements were performed by trained staff. If an infant was ill at time of a scheduled study visit, parents were instructed to contact the study team in order to reschedule the appointment.

Anthropometrics
Weight was measured with an electronic infant scale to the nearest 5 grams (SECA 717, Hamburg, Germany). Length was measured twice by two-person technique with an infantometer to the nearest 0.1 cm (SECA 416) and head circumference was measured twice as the widest frontal-occipital circumference with a measuring tape to the nearest 0.1 cm (SECA 201).

Weight-for-length, weight-for-age and height-for-age SDS were calculated by Growth Analyser (https://growthanalyser.org/; Talma, 2010).

Body composition measurements
Until age 6 months, body composition was assessed by air-displacement plethysmography (ADP by PEA POD, COSMED, Italy) as described in detail elsewhere (20). According to standard protocol, the PEA POD was calibrated daily (21). From 6 months onwards, a Dual Energy X-ray Absorptiometry (DXA) scan was performed at every visit with the same device (DXA, Lunar Prodigy, GE Healthcare, UK) and software (enCORE software version 14.1). At the
transition point of 6 months, median FM% was 24.1 by ADP and 25.0 by DXA (n=278), with a median difference of 0.9% between both measurements. Bland-Altman analysis showed no proportional bias (p=0.321) (22).

Fat mass index (FMI) was determined by dividing fat mass (kg) by height squared ($m^2$) and Fat-free mass index (FFMI) by dividing fat-free mass (kg) by height squared ($m^2$).

**Ultrasound measurement of abdominal fat mass**

Subcutaneous and visceral fat thickness were measured by ultrasound at every visit starting from 3 months of age and described in detail elsewhere (20, 23). Unsuccessful ultrasound measurements of visceral fat mass, without visualization of the lumbar vertebra, were excluded from analyses.

**Infant feeding**

Infant feeding was classified as exclusive breastfeeding (BF) if an infant received breastfeeding for at least 3 months or no exclusive breastfeeding if they received formula feeding or mixed feeding before age 3 months. Information on the timing of solid food introduction was obtained from questionnaires.

**Telomere length assessment**

Genomic DNA was isolated from peripheral leukocytes using standard procedures and the same methods were used for all samples. All LTL measurements were made in the same laboratory at the University of Leicester. Mean LTL was measured by the quantitative PCR-based technique (2, 24). Telomere sequence copy number (T) was compared with a single copy gene number in the genome 36B4 (S) and telomere length expressed as a T/S ratio. All T and S values were calculated relative to a calibrator DNA (genomic DNA from the K562 cell line) that was included on every plate. This allowed correction for inter-run variation. To further minimize any technical variation in the LTL measurements for the 3 month and 2 year samples, both samples for each individual were run within the same assay plate. All samples were checked for concordance between duplicate values for T and S as quality control. Samples showing a difference of greater than 0.2 cycles in the take-off value or amplifying outside of the linear range of the assay were excluded and re-run alongside the second time point for that individual. Reproducibility of the assay was tested by re-running samples on separate days. The mean inter-run CV for the T/S ratio was 2.85%. T/S ratio in our cohort at 3 months and 2 years were compared with T/S ratio in our PROGRAM study at 21 years. Subjects of our PROGRAM study met the same inclusion criteria of the healthy, term-born infants of present study and samples were analyzed in the same laboratory using the same technique (18).
Statistical Analysis
Clinical characteristics were expressed as median and interquartile range [IQR], and pooled means (pooled SD) in Table 1. For this study, we included 145 infants with blood collection at age 3 months and/or 2 years with ≥ 4 body composition measurements during the first 2 years of life and without past or present serious illnesses. In total, 112 infants had blood collection at both time points in which the shortening in LTL from 3 months to 2 years was determined. Differences in clinical characteristics were assessed by independent student’s t-test or Mann-Whitney U-test for non-parametric parameters. Correlations were determined by Spearman’s correlation coefficient. Missing data on body composition, mainly because of infants showing resistance at measurements, were imputed using a multiple imputation approach in SPSS to generate 20 imputed datasets. Although small differences were observed between analyses with imputed.

RESULTS
Clinical characteristics of the subjects are presented in Table 1. Of the total group, 58.6% was male and 41.4% female. Median (IQR) birthweight was 3.38 (3.11–3.90) kg at 39.9 (39.0–40.9) weeks in boys and 3.19 (2.78–3.50) kg at 39.9 (38.8–40.5) weeks in girls.

Telomere length during the first 2 years of life
Median (IQR) LTL decreased from 3 months to 2 years (T/S ratio 4.10 (3.78–4.72) vs 3.75 (3.51–4.09), p<0.001) (Table 2), which is a decrease of 8.5% from 3 months to 2 years (4.9% per year) (Fig 1). LTL at 3 months was associated with LTL at 2 years (R=0.641, p<0.001).

Figure 1. Longitudinal LTL development over time based on outcome of two separate birth cohort studies
Data are expressed as median LTL at 3 months and 2 years (current study) and mean LTL at 21 years (from our previous PROGRAM study (18)), both with upper interquartile range.
The shortening in LTL from 3 months to 2 years associated with fat mass percentage (FM%, \( R=0.193, p=0.048 \)), FM index (FMI, \( R=0.243, p=0.016 \)) and visceral FM (\( R=0.234, p=0.022 \)) at age 2 years, but not with abdominal subcutaneous FM. There was no association between LTL at age 3 months and 2 years and FM%, FMI, abdominal subcutaneous and visceral FM at the same ages.

As we previously found in the same study group that the gain in FM% from 3 to 6 months was associated with a higher FM% at 2 years, we investigated if the shortening in LTL from 3 months to 2 years was associated with the gain in FM% from 3 to 6 months. The shortening in LTL from 3 months to 2 years tended to associate with the gain in FM% from 3 to 6 months (\( R=0.155, p=0.11 \)).

LTL at age 3 months, 2 years and the shortening in LTL from 3 months to 2 years did not associate with the change in FM% and visceral FM from 3 months to 2 years.

The shortening in LTL from 3 months to 2 years associated with fat-free mass index (FFMI) at 3 months (\( R=0.223, p=0.019 \)), but not at age 2 years and not with FFM, and there was no association between LTL at age 3 months and 2 years and FFM and FFMI at the same ages.
Variables with potential influence on telomere length

**Boys and girls**

Median LTL was not different between boys and girls at age 3 months (p=0.48), but boys tended to have shorter LTL than girls at age 2 years (3.65 vs 3.86, p=0.056) (Table 2). The shortening in LTL from 3 months to 2 years was not different between boys and girls (p=0.38).

**Parental and infant variables**

Neither gestational age, parity, mode of delivery (vaginally or caesarian section), maternal pre-pregnancy BMI and weight gain during pregnancy, nor birthweight and ethnicity were associated with LTL at age 3 months, 2 years and shortening in LTL from 3 months to 2 years.

Maternal and paternal age at infant’s birth did also not associate with LTL at age 3 months, 2 years and shortening in LTL from 3 months to 2 years.

**Infant feeding**

Of 145 infants, 77 were exclusively breastfed and 68 were not exclusively breastfed. Exclusively breastfed infants had longer LTL at 3 months compared to infants without exclusive breastfeeding (T/S Ratio 4.4 vs 4.1, p=0.046), but LTL at 2 years and the shortening in LTL from 3 months to 2 years were similar in infants with exclusive BF and nonexclusive BF (p≥0.19). Duration of BF and timing of introduction of solid foods were also not correlated with LTL at 3 months, 2 years and shortening in LTL from 3 months to 2 years.

**Length and growth**

Length SDS at 3 months, 2 years and change in length SDS from 3 months to 2 years did neither associate with LTL at these ages, nor with the shortening in LTL from 3 months to 2 years.

---

**Table 2.** LTL (T/S ratio) at age 3 months and 2 years for the total group, boys and girls.

<table>
<thead>
<tr>
<th></th>
<th>LTL 3 months</th>
<th>LTL 2 years</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total group</strong></td>
<td>4.10 [3.78 – 4.72]</td>
<td>3.75 [3.51 – 4.09]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Boys</strong></td>
<td>4.05 [3.67 – 4.84]</td>
<td>3.65 [3.34 – 4.05]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Girls</strong></td>
<td>4.20 [3.86 – 4.67]</td>
<td>3.86 [3.53 – 4.29]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>P-value</strong></td>
<td>p=0.48</td>
<td>p=0.056</td>
<td></td>
</tr>
</tbody>
</table>

Data expressed as median [IQR]. Abbreviations: LTL; leukocyte telomere length, T/S ratio; Telomere to single-gene copy ratio.
DISCUSSION

Our findings in healthy, term-born infants show that 8.5% of shortening of LTL occurs from age 3 months to 2 years. The shortening in LTL from 3 months to 2 years was associated with FM%, FMI and visceral FM at age 2 years. LTL shortening during the first 2 years of life tended to associate with the gain in FM% from 3 to 6 months, within the critical window for adiposity programming.

The period from conception until age 2 years, the first 1000 days of life, is an important period for infant development (13). Prenatal exposure to damaging environmental factors and maternal stress have been associated with shorter LTL in newborns (25, 26). Leukocyte telomere length is one the biomarkers of aging (27, 28), next to other biomarkers like oxidative stress, inflammation and aberrations in protein and lipid metabolism, which could also affect aging rate (28). To our knowledge, however, a very limited number of studies describe longitudinal data on LTL during infancy as most studies have used neonatal cord blood to investigate LTL at birth (15, 16) or investigated LTL cross-sectionally (17, 29). We investigated longitudinal values for LTL at age 3 months and 2 years based on a large group of healthy, term-born infants and show that LTL decreases considerably during the first 2 year of life. There is one other paper about the change in LTL from infancy to age 2 and 3 years (12). Our findings are in line in describing an impressive decline in LTL during the first 2 years of life. However, in contrast to the study by Bosquet Enlow et al., our first LTL measurement took place at age 3 months, thus during the critical window for adiposity programming from birth to age 6 months (7, 8), while they measured LTL for the first time at a mean age of 8.6 months.

Our findings show that LTL decreases with 8.5% from age 3 months to 2 years, which is a decline of 4.9% per year. In our PROGRAM study, LTL was investigated at age 21 years in 284 healthy, term-born subjects in the same laboratory using the same technique (18). These subjects met the same inclusion criteria as the healthy, term-born infants of present study. We showed that LTL declined with 13.3% from age 2 years to 21 years, which is 0.7% per year after infancy, indicating that telomeres might shorten more during the first 2 years of life compared to the period from age 2 years to 21 years. Longitudinal studies from birth to 21 years have to confirm the abovementioned decline in the same subjects instead of comparing two cohorts of healthy, term-born subjects, but our findings are in line with the study by Bosquet Enlow et al. describing a stable LTL from age 2 until 3 years (12).

The shortening in LTL from age 3 months to 2 years associated significantly with FM% and FMI at age 2 years, indicating that infants with more adiposity at age 2 years had more shortening of telomeres in the period from 3 months to 2 years. Shortening in LTL from
age 3 months to 2 years also associated with abdominal visceral FM at age 2 years. This is in line with a study in healthy children and adults showing that those with higher total and abdominal adiposity have lower telomere length (30). More visceral FM has been associated with unfavorable metabolic health profiles (31, 32) and we now show that shortening in LTL during infancy is associated with visceral FM at age 2 years.

As we have shown that particularly more gain in FM% SDS from 3 to 6 months, the critical window for adiposity programming, was associated with a higher FM% at age 2 years (10), we investigated whether the shortening in LTL in the first 2 years was associated with the gain in FM% from 3 to 6 months. We found that the shortening in LTL from 3 months to 2 years tended to associate with the gain in FM% from 3 to 6 months, which could indicate that a higher gain in FM% in the critical window for adiposity programming might accelerate the shortening of LTL. It has been reported that early life adiposity programming could potentially be an early life stressor by inducing oxidative stress, which would accelerate telomere shortening (33, 34). Also early onset of obesity has been associated with shorter LTL in children at a mean age of 11 years (35). Our findings suggest that adverse adiposity programming in early life could contribute to more shortening of LTL.

Shortening in LTL from 3 months to 2 years also associated with FFMI at 3 months, but not at 2 years. Longer telomeres at birth have been associated with more lean mass during late infancy (15), which is in line with our results. We have, however, no data on LTL at birth and were therefore not able to study LTL and FFMI from birth onwards.

LTL was similar in boys and girls at 3 months, which has been reported in newborns (36, 37). At 2 years, however, boys tended to have shorter LTL compared to girls, which is in line with findings during infancy, childhood and adulthood, when females have longer telomeres (12, 17, 38). For final conclusions about sex differences in LTL, more research is required in a larger study group.

No correlations were found between LTL and birthweight and gestational age in our large group of term-born, mainly appropriate-for-gestational age infants, which is in contrast to a study describing lower birthweight result in lower cord blood LTL (39). This study, however, also included premature infants where we only included term-born infants and in addition most of the infants in our study had a birthweight between -2 and +2 SDS. There was no correlation between cord blood LTL and gestational age, similar to our findings. Our findings are also in line with studies investigating LTL in healthy subjects at 11 years (40) and at adult age (11). Shorter LTL has mainly been found in children born with very low birthweight (41) or born prematurely (18).
Maternal pre-pregnancy BMI did not correlate with infant LTL. This is in contrast to a study describing an association between maternal pre-pregnancy BMI and shorter newborn LTL. We, however, investigated LTL at age 3 months and 2 years instead of birth. Future research is needed to investigate pre-pregnancy BMI and LTL in different pre-pregnancy BMI classes. Maternal and paternal age did not associate with LTL until age 2 years, which is in line with literature (12).

The strength of this study is the collection of longitudinal blood samples for investigating LTL in combination with the longitudinal body composition measurements in healthy infants until the age of 2 years. We did not adjust for social economic status (SES) as we and others have shown that SES did not associate with LTL at any age (12, 18, 42). The effect of SES on the decline of LTL during the first 2 years of life seems therefore limited, but a definite answer would require more research.

Conclusions
In conclusion, we present longitudinal values of LTL and show that telomere length decreases by 8.5% from age 3 months to 2 years. Shortening in LTL during the first 2 years of life was associated with FM%, FMI and visceral FM at 2 years. LTL shortening during the first 2 years of life tended to associate with a higher gain in FM% from 3 to 6 months, suggesting that adverse adiposity programming during the critical window for adiposity programming could contribute to more LTL shortening in early life.

Acknowledgments
We would like to thank all parents and children for participating in the Sophia Pluto Study. Furthermore, we greatly acknowledge Ms. J. van Nieuwkastelee, Mrs. M. Huibregtse-Schouten, Mrs. C. Bruinings-Vroombout, Mrs. E. Lems, Ms. N. Khieroe, Mrs. S. Besteman-Voortman, Mrs. J. Bontenbal-van de Wege, research nurses, for their assistance with data collection.
REFERENCES


15. COSMED. Pea Pod Brochure ENGLISH